

DAFTAR PUSTAKA

- Abbasi, A., Bhutto, A. R., Butt, N. and Munir, S. M. (2012) 'Corelation of serum alpha fetoprotein and tumor size in hepatocellular carcinoma Original Article Corelation of serum alpha fetoprotein and tumor size in hepatocellular carcinoma', *J Pak Med Assoc*, 62(May 2014), pp. 33–36.
- Abdel-Misih, S. R. Z. and Bloomston, M. (2010) 'Liver Anatomy', *Surgical Clinics of North America*. Elsevier Ltd, 90(4), pp. 643–653. doi: 10.1016/j.suc.2010.04.017.
- Anis, M. (2011) 'Imaging of Hepatocellular Carcinoma : Practical Guide to Diffeerential Diagnosis', *liver.theclinics.com*, 15, pp. 335–352. doi: 10.1016/j.cld.2011.03.014.
- Bağırsakçı, E., Şahin, E., Atabey, N., Erdal, E., Guerra, V. and Carr, B. (2017). Role of Albumin in Growth Inhibition in Hepatocellular Carcinoma. *Oncology*, 93(2), pp.136-142. doi: 10.1159/000471807
- Bai, D., Zhang, C., Chen, P., Jin, S. and Jiang, G. (2017) 'The prognostic correlation of AFP level at diagnosis with pathological grade , progression , and survival of patients with hepatocellular carcinoma', *Scientific Reports*. Springer US, (September), pp. 1–9. doi: 10.1038/s41598-017-12834-1.
- Bernardi, M., Ricci, C. and Zaccherini, G. (2014). Role of Human Albumin in the Management of Complications of Liver Cirrhosis. *Journal of Clinical and Experimental Hepatology*, 4(4), pp.302-311. doi:10.1186/cc11218
- Bruix, J. and Sherman, M. (2011) 'Management of hepatocellular carcinoma: An update', *Hepatology*, 53(3), pp. 1020–1022. doi: 10.1002/hep.24199.
- Caraceni, P., Domenicali, M., Tovoli, A., Napoli, L., Ricci, C., Tufoni, M. and Bernardi, M. (2013). Clinical indications for the albumin use: Still a controversial issue. *European Journal of Internal Medicine*, 24(8), pp.721-728.
- Carr, B. and Guerra, V. (2017). Serum Albumin Levels in Relation to Tumor Parameters in Hepatocellular Carcinoma Patients. *The International Journal of Biological Markers*, 32(4), pp.391-396. doi: 10.5301/ijbm.5000300

- Carr, B., Akkiz, H., Guerra, V., Üsküdar, O., Kuran, S., and Araoğullarından, Ü.(2018) 'C-reactive protein and hepatocellular carcinoma: analysis of its relationships to tumor factors' *Clin. Pract.* 15(SI),p.625-634
- Cholankeril, G., Patel, R., Khurana, S., & Satapathy, S. K. (2017). Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management. *World Journal of Hepatology*, 9(11), 533. doi:10.4254/wjh.v9.i11.533
- Dahlan, M.S. 2013. Besar Sampel dan Cara Pengambilan Sampel dalam Penelitian Kedokteran dan Kesehatan. 3rd ed. A. Suslia, ed. Jakarta: Salemba Medika.
- El-Serag, H. B., Marrero, J. A., Rudolph, L. and Reddy, K. R. (2008) 'Diagnosis and Treatment of Hepatocellular Carcinoma', *Gastroenterology*, 134(6), pp. 1752–1763. doi: 10.1053/j.gastro.2008.02.090.
- El-Serag, H. B. and Rudolph, K. L. (2007) 'Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis', *Gastroenterology*, 132(7), pp. 2557–2576. doi: 10.1053/j.gastro.2007.04.061.
- Ellis, H. (2011) 'Anatomy of the liver', *Surgery*. Elsevier Ltd, 29(12), pp. 589–592. doi: 10.1016/j.mpsur.2011.09.012.
- Farazi, P. A. and DePinho, R. A. (2006) 'Hepatocellular carcinoma pathogenesis: From genes to environment', *Nat Rev Cancer*, 6(9), pp. 674–687. doi: 10.1038/nrc1934.
- Ferlay, J., Soerjomataram I, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman D, D. and Bray, F. (2015) 'Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.', *Int J Cancer*, 136(5), pp. E359-386. doi: 10.1002/ijc.29210.
- Grandhi, M. S., Kim, A. K., Ronnekleiv-Kelly, S. M., Kamel, I. R., Ghasebeh, M. A. and Pawlik, T. M. (2016) 'Hepatocellular carcinoma: From diagnosis to treatment', *Surgical Oncology*. Elsevier Ltd, 25(2), pp. 74–85. doi: 10.1016/j.suronc.2016.03.002.
- Javed, M., Un, G. and Tayyab, N. (2015) 'Does Value of Alpha Fetoprotein Matter in HCC ?', *P J M H S*, 9(1), pp. 2014–2016.
- Jemal, A., Bray, F. and Ferlay, J. (1999) 'Global Cancer Statistics: 2011', *CA Cancer J Clin*, 49(2), p. 1,33-64. doi: 10.3322/caac.20107.Available.

- Kruehl, C. D. P. and Scaffaro, L. A. (2017) 'Review Article Hepatocellular Carcinoma: Diagnosis And Operative Management', 30(4), pp. 272–278.
- Loho, I., Hasan, I., Lesmana, C., Dewiasty, E. and Gani, R. (2016). Hepatocellular Carcinoma in a Tertiary Referral Hospital in Indonesia: Lack of Improvement of One-Year Survival Rates between 1998-1999 and 2013-2014. *Asian Pacific Journal of Cancer Prevention*, 17(4), pp.2165-2170.
- Meza-Junco, J., Montano-Loza, A. J., Liu, D. M., Sawyer, M. B., Bain, V. G., Ma, M. and Owen, R. (2012) 'Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how?', *Cancer Treatment Reviews*. Elsevier Ltd, 38(1), pp. 54–62. doi: 10.1016/j.ctrv.2011.05.002.
- Padhya, K. T., Marrero, J. A. and Singal, A. G. (2013) 'Recent advances in the treatment of hepatocellular carcinoma', *Curr Opin Gastroenterol*, 29(3), pp. 285–292. doi: 10.1097/MOG.0b013e32835ff1cf.
- Parkin, D. M., Bray, F., Ferlay, J. and Pisani, P. (2002) 'Global cancer statistics, 2002', *CA Cancer J Clin*, 55(2), pp. 74–108. doi: 10.3322/canjclin.55.2.74.
- Rabouhans, J. S., Baron, a, Cazejust, J. and Rosmorduc, O. (2011) 'A radiologist's guide to the modified Response Evaluation Criteria in Solid Tumours (mRECIST) assessment of therapy for hepatocellular carcinoma', *ESR*, Poster C-2, pp. 1–42. doi: 10.1594/ecr2011/C-2120.
- Sanyal, A. J., Yoon, S. K. and Lencioni, R. (2010) 'The Etiology of Hepatocellular Carcinoma and Consequences for Treatment', *The Oncologist*, 15(Supplement 4), pp. 14–22. doi: 10.1634/theoncologist.2010-S4-14.
- Sastroasmoro, S. & Ismael, S. 2011. Usulan Penelitian. In S. Sastroasmoro & S. Ismael, eds. *Dasar-dasar Metodologi Penelitian Klinis*. Jakarta: Sagung Seto, pp. 31–63.
- Schütte, K., Schulz, C. and Malfertheiner, P. (2014) 'Hepatocellular Carcinoma: Current Concepts in Diagnosis, Staging and Treatment', *Gastrointestinal Tumors*, 1(2), pp. 84–92. doi:10.1159/000362583.
- Shimokawa, Y., Okuda, K., Kubo, Y., Kaneko, A., Arishima, T., Nagata, E., Hashimoto, M., Sawa, Y., Nagasaki, Y., Kojiro, M., Sakamoto, K. and Nakashima, T. (1977) 'Serum glutamic oxalacetic transaminase/glutamic pyruvic transaminase ratios in hepatocellular carcinoma', *Cancer*, 40(1), pp. 319–324.

- Siregar, G. and Buulolo, B. (2018). Factors associated with tumor size of hepatocellular carcinoma. *IOP Conference Series: Earth and Environmental Science*, 125, p.012137. doi :10.1088/1755-1315/125/1/012137
- Stankevièiûtë, L. and Maðalaitë, L. (2016) ‘Alfa fetoproteino koncentracijos koreliacija su hepatoceliulinës karcinomos dydþiu ir þidiniø skaièiumi’, *Laboratorine Medicina*, 1(1), pp. 29–32.
- Waller, L. P., Deshpande, V. and Pysopoulos, N. (2015) ‘Hepatocellular carcinoma: A comprehensive review’, *World J Hepatol*, 7(26), pp. 2648–2663. doi: 10.4254/wjh.v7.i26.2648.
- Wang, X. P., Mao, M. J., He, Z. L., Zhang, L., Chi, P. D., Su, J. R., Dai, S. Q. and Liu, W. L. (2017) ‘A retrospective discussion of the prognostic value of combining prothrombin time(PT) and fibrinogen(Fbg) in patients with Hepatocellular carcinoma’, *Journal of Cancer*, 8(11), pp. 2079–2087. doi: 10.7150/jca.19181.